Investors Can Lead Capricor Therapeutics Securities Lawsuit
Investors have an opportunity to lead a class action lawsuit against Capricor Therapeutics. The suit alleges potential violations of securities laws.
A class action lawsuit has been filed against Capricor Therapeutics, a biotechnology company, alleging potential violations of securities laws. The law firm Schall, Brown & Schwartz LLP (SBS), which focuses on shareholder rights litigation, is seeking investors to lead this action.
The lawsuit claims that Capricor Therapeutics made misleading statements and failed to disclose material information regarding the company's commercial operations and drug development. Specifically, the suit references the company's efforts in developing and marketing its cardiovascular treatment, known as Cardio1 (DC-101).
Investors are encouraged to contact SBS for further details about the lawsuit and potential involvement. The deadline to file a claim is approaching, and a lead plaintiff is expected to be appointed.
Capricor Therapeutics is focused on developing treatments for cardiovascular diseases. The company's stock is traded on the NASDAQ under the ticker symbol CAPR.